{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:02:49Z","timestamp":1780142569523,"version":"3.54.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:p>The uptake of generic immunosuppressants lags comparatively to other drug classes, despite that the Food and Drug Administration (FDA) uses identical bioequivalence standards for all drugs. Transplant societies acknowledge the cost savings associated with generic immunosuppressants and support their use following heart, lung, kidney, or bone marrow transplantation. Seven studies of the pharmacokinetics or clinical efficacy of generic mycophenolate mofetil compared to the innovator product are published; all studies and products were ex-United States. Three studies did not demonstrate any pharmacokinetic differences between generic and innovator products in healthy subjects, achieving FDA bioequivalence requirements. Two studies in renal allograft recipients demonstrated no difference in area under the curves between generic and innovator products, and in one, the maximum concentration (Cmax) fell outside the FDA regulatory range. Two studies revealed no difference in acute organ rejection or graft function in renal allograft recipients. Patient surveys indicate that cost is a barrier to immunosuppressant adherence. Generics present a viable method to reduce costs to payers, patients, and health care systems. Adherence to immunosuppressants is crucial to prevent graft failure. An affordable regimen potentially confers greater adherence. Concerns regarding the presumed inferiority of generic immunosuppressants should be assuaged by regulatory requirements for bioequivalency testing, transplant society position statements, and pharmacokinetic and clinical studies.<\/jats:p>","DOI":"10.1177\/0897190015585758","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T21:05:49Z","timestamp":1433451949000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Is There Evidence to Support Brand to Generic Interchange of the Mycophenolic Acid Products?"],"prefix":"10.1177","volume":"30","author":[{"given":"Karen","family":"Phillips","sequence":"first","affiliation":[{"name":"Partners HealthCare, Needham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabashni","family":"Reddy","sequence":"additional","affiliation":[{"name":"Partners HealthCare, Needham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gabardi","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"bibr1-0897190015585758","unstructured":"Generic Pharmaceutical Association: about generic medications. Web site. http:\/\/www.gphaonline.org\/about\/generic-medicines. Updated 2013. Accessed June 12, 2014."},{"key":"bibr2-0897190015585758","unstructured":"The 2013 Drug Trend Report. The Express Scripts Lab. Web site. http:\/\/lab.express-scripts.com\/drug-trend-report. Published April 2014. Accessed July 14, 2014."},{"key":"bibr3-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.504"},{"key":"bibr4-0897190015585758","unstructured":"Food and Drug Administration Therapeutic Equivalence of Generic Drugs-Response to National Association of Boards of Pharmacy; April 17, 1997. Web site. http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/AbbreviatedNewDrugApplicationANDAGenerics\/ucm073224.htm. Accessed June 12, 2014."},{"key":"bibr5-0897190015585758","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research Approved Drug Products CellCept. Web site. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Published June 19, 1997. Accessed June 12, 2014."},{"key":"bibr6-0897190015585758","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research Approved Drug Products. Web site. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Published February 27, 2004. Accessed June 12, 2014."},{"key":"bibr7-0897190015585758","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products\u2014General Considerations; 2003. Web site. http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm070124.pdf. Published March 2003. Accessed June 12, 2014."},{"key":"bibr8-0897190015585758","unstructured":"Food and Drug Administration Abbreviated New Drug Application (ANDA): generics. Web site. http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/AbbreviatedNewDrugApplicationANDAGenerics\/default.htm. Accessed May 24, 2015."},{"key":"bibr9-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M141"},{"key":"bibr10-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12074"},{"key":"bibr11-0897190015585758","unstructured":"Health Canada Guidance Document Conductance and Analysis of Comparative Bioavailability Studies; 2012. Web site. http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/pdf\/prodpharma\/applic-demande\/guide-ld\/bio\/gd_cbs_ebc_ld-eng.pdf. Published May 22, 2012. Accessed June 12, 2014."},{"key":"bibr12-0897190015585758","unstructured":"Health Canada Guidance Document Comparative Bioavailability Standards: formulations used for systemic effects; 2012. Web site. http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/pdf\/prodpharma\/applic-demande\/guide-ld\/bio\/gd_standards_ld_normes-eng.pdf. Published May 22, 2012. Accessed June 12, 2014."},{"key":"bibr13-0897190015585758","unstructured":"European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. Committee for Proprietary Medicinal Products Note for Guidance on the Investigation of Bioavailability and Bioequivalence; 2001. Web site. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003008.pdf. Published July 26, 2001. Accessed June 12, 2014."},{"key":"bibr14-0897190015585758","unstructured":"European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. Committee for Proprietary Medicinal Products Note for Guidance on the Investigation of Bioavailability and Bioequivalence; 2010. Web site. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf. Published January 20, 2010. Accessed June 12, 2014."},{"key":"bibr15-0897190015585758","unstructured":"European Medicines Agency Questions & Answers: positions on specific questions addressed to the pharmacokinetics working party; 2013. Web site. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002963.pdf. Published February 13, 2013. Accessed July 17, 2013."},{"key":"bibr16-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.03.008"},{"key":"bibr17-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2003.11.008"},{"key":"bibr18-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.03.055"},{"key":"bibr19-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2006.12.034"},{"key":"bibr20-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2012.01475.x"},{"key":"bibr21-0897190015585758","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07111009"},{"key":"bibr22-0897190015585758","first-page":"292","volume":"4","author":"Abdallah T","year":"2010","journal-title":"Exp Clin Transplant"},{"key":"bibr23-0897190015585758","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.882222"},{"key":"bibr24-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R028"},{"key":"bibr25-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2011.01268.x"},{"key":"bibr26-0897190015585758","unstructured":"Bentley T, Hanson S, Hauboldt R, 2011 U.S. organ and tissue transplant cost estimates and discussion Milliman Research Report. Web site. http:\/\/publications.milliman.com\/research\/health-rr\/pdfs\/2011-us-organ-tissue.pdf. Published April 30, 2011. Accessed June 12, 2014."},{"issue":"1","key":"bibr27-0897190015585758","first-page":"26","volume":"19","author":"Tschida S","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"bibr28-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2003.00212.x"},{"key":"bibr29-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182445e9d"},{"key":"bibr30-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2011.01378.x"},{"key":"bibr31-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.11.006"},{"key":"bibr32-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2009.05.001"},{"key":"bibr33-0897190015585758","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.377"},{"key":"bibr34-0897190015585758","unstructured":"Thomson Reuters Micromedex Clinical Evidence Solutions [Internet]. Thomson Reuters. RED BOOK Drug References; 2014. Web site. http:\/\/thomsonreuters.com\/products_services\/healthcare\/healthcare_products\/clinical_deci_support\/micromedex_clinical_evidence_sols\/med_safety_solutions\/red_book\/. Updated weekly. Accessed November 15, 2014."}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190015585758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190015585758","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190015585758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:33Z","timestamp":1777509393000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190015585758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1177\/0897190015585758"],"URL":"https:\/\/doi.org\/10.1177\/0897190015585758","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}